Simple Summary Women with a BRCA1 or BRCA2 gene mutation have up to an 80%
lifetime risk of breast cancer unless their breasts are surgically removed, but many decline or …

Female BRCA1/BRCA2 mutation carriers are at substantially increased risk for developing
breast and/or ovarian cancer, and are offered enhanced surveillance including screening …

Purpose To evaluate the real-life performance of a breast cancer screening program for
women with different categories of increased breast cancer risk with multiple follow-up …

A systematic review of the literature was conducted to assess the outcomes of preventive
interventions (prophylactic surgery, intensive cancer screening, and chemoprevention) in …

Women with a genetic predisposition to breast cancer may be at increased risk of cancer
after exposure to ionizing radiation. It is unclear whether mammography screening …

The development of intervention strategies for carriers of mutations in the BRCA1 and
BRCA2 genes has several considerations. The first are primary prevention and secondary …

Women with BRCA mutations, who choose to decline or defer risk-reducing mastectomy,
require a highly sensitive breast screening regimen they can begin by age 25 or 30. Meta …

BACKGROUND: Women at a high risk for breast cancer are offered choices for screening or
prophylactic surgeries. The aim of this study was to evaluate opinions regarding screening …

Background Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian
cancer. In the current study, we report on uptake of cancer screening and risk-reduction …

Background Hormone therapy (HT) is commonly given to women to alleviate the climacteric
symptoms associated with menopause. There is concern that this treatment may increase …